97. Ulcerative colitis Clinical trials / Disease details


Clinical trials : 2,527 Drugs : 1,465 - (DrugBank : 259) / Drug target genes : 144 - Drug target pathways : 202

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-JapicCTI-132135
01/5/2013Phase III Study of Z-206Phase III Study of Z-206 Ulcerative ColitisIntervention name : Z-206
INN of the intervention : Mesalazine
Dosage And administration of the intervention : Mesalazine at the dose 2.4g/day is administered once a day or three times a day.
Control intervention name : null
Zeria Pharmaceutical Co., Ltd.Kyowa Hakko Kirin Co., Ltd.1664BOTH600Phase 3NULL
2JPRN-C000000288
2005/12/0121/11/2005Z-206 Phase III Clinical Trial- Investigation on the remission-inducing effect in patients with ulcerative colitis in active phase - Patients with ulcerative colitis in active phaseZ-206 2.4g/day dose group: Two Z-206 400mg tablets, 1 tablet of Z-206 placebo tablet, 3 tablets of Pentasa placebo tablet per time (total 6 tablets).
3 times a day (t.i.d.) after each meal for 8 weeks.
Z-206 3.6g/day dose group: Three tablets of Z-206 400mg tablet, 3 tablets of Pentasa placebo tablet per time (total 6 tablets).
3 times a day (t.i.d.) after each meal for 8 weeks.
Mesalazine group: Three tablets of Pentasa 250 mg tablet and 3 tablets of Z-206 placebo tablet per time (total 6 tablets).
3 times a day (t.i.d.) after each meal for 8 weeks.
Placebo group: Three tablets of Z-206 placebo tablet and 3 tablets of Pentasa placebo tablet per time (total 6 tablets).
3 times a day (t.i.d.) after each meal for 8 weeks.
Zeria Pharmaceutical Co.,LTD.NULLComplete: follow-up complete16years-old64years-oldMale and Female210Phase 3Japan
3JPRN-C000000289
2005/12/0121/11/2005Z-206 Phase III Clinical Trial- Investigation on the remission-maintaining effect in patients with ulcerative colitis in remission phase - Patients with ulcerative colitis in remission phase.Z-206 group : Two Z-206 400 mg tablets, 3 tablets of Pentasa placebo tablet per time (total 5 tablets).
3 times a day (t.i.d.) after each meal for 48 weeks.
Mesalazine group: Three tablets of Pentasa 250 mg tablet and 2 tablets of Z-206 placebo tablet per time (total 5 tablets).
3 times a day (t.i.d.) after each meal for 48 weeks.
Zeria Pharmaceutical Co.,LTD.NULLComplete: follow-up complete16years-old64years-oldMale and Female120Phase 3Japan
4JPRN-JapicCTI-121943
30/08/2012Phase II Study of Z-206Phase II Study of Z-206 Ulcerative colitisIntervention name : Z-206
INN of the intervention : Mesalazine
Dosage And administration of the intervention : oral
Zeria Pharmaceutical Co., Ltd.Kyowa Hakko Kirin Co., Ltd.BOTHPhase 2NULL